Related Experiment Video

Updated: Aug 6, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer

Aida Jlassi1,2, Maroua Manai1,3,4, Maram Morjen5

  • 1Department of Biology, Mycology, Pathologies and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia.

Plos One
|March 23, 2023
PubMed

Insights

V-domain Ig suppressor of T cell activation (VISTA) is expressed in ovarian cancer and associated with CD8+ T cells. The VISTA+/CD8+ subtype indicates prolonged overall survival, suggesting VISTA as a potential immunotherapy target.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Immunotherapy targeting immune checkpoint regulators is a promising cancer treatment.
  • V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator identified in ovarian cancer.

Purpose of the Study:

  • To investigate the role of VISTA in Epithelial ovarian cancer (EOC).
  • To analyze the relationship between VISTA, tumor-infiltrating lymphocytes (TILs), and prognostic value in EOC.

Main Methods:

  • Assessed VISTA, CD3, CD8, CD4, FOXP3, and CD56 expression in 168 EOC tissue microarrays (TMA) using immunohistochemistry (IHC).
  • Evaluated VISTA expression in IGRov1 cells and peripheral blood mononuclear cells (PBMC) of EOC patients via western blot.
  • Analyzed associations between VISTA, TILs, clinicopathological variables, and overall survival (OS).

Main Results:

  • VISTA was detected in 64.28% of EOC tissues, with expression in tumor cells (42.3%) and immune cells (47.9%).
  • VISTA expression in immune cells correlated significantly with high densities of CD3+, CD4+, and CD8+ TILs.
  • The VISTA+/CD8+ immune subtype was significantly associated with prolonged OS, while VISTA+/CD8- correlated with the worst OS.

Conclusions:

  • VISTA is highly expressed in EOC and associated with CD8+ TILs.
  • The dual positive VISTA+/CD8+ subtype is linked to improved overall survival in EOC patients.
  • VISTA represents a potential immunotherapeutic target for Epithelial ovarian cancer.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.3K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
406
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Odds Ratio01:09

Odds Ratio

The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
200